Joining our Avesta76 SPV Due Diligence Team

Our Avesta76 SPV Due Diligence team is evaluating an opportunity to co-lead Avesta76’s Seed Round raise to support IND application and clinical trials for its antisense oligonucleotide (ASO) candidate. CANCER FUND would be partnering with a global merchant bank with over half a billion dollars invested into early-stage companies across a large variety of sectors, providing our expertise in early stage cancer therapeutics to benchmark Avesta76’s current progress and help guide the company’s clinical and technical activities forward.

To be considered for this team, please review and respond to the questions below: